We at Moleac are genuinely concerned about people’s well-being, and we are committed to manufacturing the best possible products to improve their health. To ensure safety and efficacy for a variety of conditions, NeuroAiD™ has been and continues to be thoroughly tested, and the results are published in peer-reviewed medical journals.
Two common questions that people have concern the safety and clinical efficacy of NeuroAiD™. In a dedicated effort to provide quality products and service, we continuously survey our customers and monitor their progress. Shown below are the results of a recent survey regarding patients who purchased NeuroAiD™ for at least one month (inclusive) of treatment between January 1, 2011, and December 31, 2011. Customers were emailed an online questionnaire in three different languages—English, French, and Spanish. We received 112 answers, which form the basis for the charts below. We would like to share these insights with you.
Tolerance to NeuroAiD™
NeuroAiD™ is a natural product with no known drug interactions, and several studies have proven that it is safe to use. Our customer report supports the findings in these clinical studies: 96% of patients report no side effects when taking NeuroAiD™.
Side effects that were reported have been mild and usually in the form of digestive discomfort (due to the high herbal concentration), allergy, or headache.
Efficacy of NeuroAiD™
Many factors can affect the results of NeuroAiD™ treatment, including the age of the patient, the diverse nature of strokes, and the degree of rehabilitation intensity that patients undergo. Accordingly, although results vary from patient to patient, we are happy to say that 70% of patients show improvement after taking NeuroAiD™.
The reported efficacy tends to be better in patients who have suffered a recent stroke.
The take home message
We are pleased to note that reported tolerability and efficacy are similar to results reported in published clinical studies and previous NeuroAiD™ customer surveys. We must stress, however, that NeuroAiD™ is not a miracle cure. Its effect depends upon patient characteristics and the nature of the stroke and rehabilitation routine. Once again, we are happy to say that about 70% of customers have reported improvement, but we must mention that approximately 30% have not noticed improvement while on NeuroAiD™ (this includes people who may not have completed the full three months treatment). 70% of the respondents indicated that they would recommend someone in their situation to take NeuroAiD™.